Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting

Author's Avatar
Nov 03, 2022

Alpine+Immune+Sciences%2C+Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today presented a poster at the American+Society+of+Nephrology+Kidney+Week+2022+Meeting highlighting updated clinical data from RUBY-1, a phase 1 healthy volunteer (HV) study of ALPN-303, a dual B cell cytokine antagonist being developed for multiple B cell and/or autoantibody-related diseases.